RoboCT Secures Investment from Pappas Capital to Advance Exoskeleton Robotics in Tech-Enabled Rehabilitation and Elderly Care

Recently, Hangzhou RoboCT Technology Development Co., Ltd. (hereinafter referred to as “RoboCT”), a global leader in exoskeleton technology, announced the introduction of international investor Pappas Capital, along with continued additional investment from its existing shareholder, Hangzhou Yuhang Financial Holdings Group Co., Ltd. Leveraging this opportunity, RoboCT will accelerate the deployment of its international business development and significantly increase talent acquisition and investment in R&D and marketing across global markets. Furthermore, RoboCT will further deepen collaborations with top-tier international research and clinical institutions to promote its rehabilitation exoskeleton technology service platform based on the innovative Robotics-as-a-Service (RaaS) model, thereby consolidating its leading position in the industry.It is reported that RoboCT hasBecomeAllBallWithin the rangeRehabilitationThe company with the highest number of exoskeletons deployed and utilized.

Pappas Capital, a globally leading venture capital firm, boasts an impressive 29-year track record in investing in cutting-edge life sciences and technology enterprises. The funds managed by Pappas Capital have successfully invested in more than 100 early-stage startups, with their developed technologies and products cumulatively receiving 25 “Best-in-Class/First-in-Class” approvals from the U.S. Food and Drug Administration (FDA). The participation of Pappas Capital as an investor has opened new channels for RoboCT to diversify its financing opportunities and established partnerships that facilitate the commercialization of its rehabilitation exoskeleton products.

Art Pappas, Managing Partner at Pappas Capital, expressed strong recognition for RoboCT’s R&D capabilities and products. “We are delighted to support RoboCT in the development and commercialization of exoskeleton products that have the potential to transform human lives. RoboCT’s rehabilitation exoskeleton services significantly enhance medical outcomes and prioritize patient care, demonstrating impressive potential.”

Previously, RoboCT’s Series A and Series A+ financing rounds secured resource support from leading domestic and international funds, including Fortune Capital, BlueRun Ventures, Essence Securities, and Poly Capital. This enabled the company to complete key milestones, including mass production of exoskeletons, in-house development of core hardware, product iteration, establishment of technical innovation barriers, and commercial validation. With the assistance of strategic cornerstone investor Natong Technology, RoboCT finalized early-stage product design and completed clinical registration, laying a foundational framework while expanding its business lines into orthopedics and sports medicine.

As a national-level high-tech enterprise, RoboCT is dedicated to the research, development, and application of foundational technologies for exoskeleton robots, including core algorithms and key components. To date, the company has independently filed over 500 intellectual property applications, with more than 300 grants awarded, and was honored with the China Patent Silver Award in 2023. As an “innovative Class II medical device,” RoboCT’s self-developed and self-manufactured rehabilitation exoskeleton equipment became the first project in China to obtain the National Medical Products Administration (NMPA) registration certificate for neurological rehabilitation, filling a domestic gap. Appraised by authoritative societies and associations, its overall technical level has reached an internationally leading position within the industry.

In terms of commercialization progress, RoboCT stands out in the industry for both the intensity and effectiveness of its exoskeleton marketing efforts. By introducing the innovative “Rehabilitation as a Service” concept, the company has rapidly brought the new direction of “digital rehabilitation,” based on exoskeleton robot technology, to professional rehabilitation institutions. Over the past two years, its solutions have been deployed in more than 560 rehabilitation centers, disabled persons’ federation agencies, and hospitals, covering over 92% of China’s provincial-level administrative regions and serving more than 300,000 patient visits cumulatively. Recently, RoboCT’s pediatric exoskeleton product, the KidGo series of rehabilitation exoskeletons, obtained additional Class II medical device registration certification from the National Medical Products Administration (NMPA), which will undoubtedly continue to facilitate the expansion of the rehabilitation exoskeleton market.

Dr. Wang Tian, Founder and CEO of RoboCT, stated when discussing his original motivation for starting the business, “Exoskeleton robots are essentially products that amplify and empower human physical capabilities, fulfilling humanity’s aspiration to become stronger. The core mission lies in addressing the rehabilitation and elderly care challenges that everyone will inevitably face through exoskeleton-based rehabilitation technology.”

Undeniably, China’s rapid development in robotics and manufacturing has laid a solid foundation for rehabilitation exoskeleton robot technology. The market adoption and widespread application of domestically produced rehabilitation exoskeleton robots will accelerate innovation and development in rehabilitation technology. RoboCT’s competitive products will foster growth in the international market, promote international cooperation and exchange in the field of rehabilitation technology, and lead global advancements in rehabilitation exoskeleton robot technology.

Exoskeleton technology is a groundbreaking innovation that offers humanity an entirely new quality of life. In the medical field, exoskeleton technology can be applied to rehabilitation therapy, helping individuals with disabilities regain mobility and improve their quality of life. In the consumer sector, it can provide older adults with a more comfortable and safe living environment, enabling them to maintain social connections and independence for longer periods.

RoboCT is committed to continuous product innovation, improving the economic accessibility of exoskeletons, and expanding patients’ opportunities to use and benefit from this transformative technology. RoboCT also looks forward to collaborating with customers and partners worldwide to jointly advance the development of life sciences and create a better future for humanity.

“RoboCT,” established in 2017, is a national high-tech enterprise driven by technological innovation. It is dedicated to the research, development, and application of exoskeleton robot technologies, including core algorithms and key components. Currently focusing on the fields of rehabilitation and elderly care, it provides intelligent products and solutions to medical and wellness institutions as well as individual users by integrating human-computer interaction technology, data analytics, and cloud computing.

RoboCT is committed to benefiting individuals with motor impairments and mobility limitations caused by neurological injuries. By leveraging robotics technology to enhance human physical capabilities, the company aims to expand the application of exoskeleton technology across industries such as industrial manufacturing, healthcare, safety, transportation, and entertainment, striving toward the vision of “Human Plus” and ultimately enabling everyone to benefit from robotic services. RoboCT’s core product portfolio comprises four major segments: core components and industrial applications, rehabilitation medicine, consumer-grade health and elderly care, and innovative smart applications. These solutions address rehabilitation, mobility, and self-care challenges for individuals with disabilities or limited physical abilities.

Pappas Capital, a globally leading venture capital firm headquartered in North Carolina’s Research Triangle Park, boasts a distinguished 29-year track record in investing in cutting-edge life sciences and technology enterprises. The funds managed by Pappas Capital have successfully invested in more than 100 early-stage startups, whose technologies and products have collectively received 25 “Best-in-Class/First-in-Class” approvals from the U.S. Food and Drug Administration (FDA).

Driven by an unwavering commitment to innovation, Pappas Capital’s US dollar-denominated thematic fund, the Asia Innovation Ventures (AIV) Fund, is actively investing in early-stage next-generation technology companies across Mainland China, Hong Kong SAR, and Singapore. Meanwhile, Pappas Capital’s flagship fund, Pappas Ventures, continues to focus on supporting early-stage life sciences companies in the United States and Canada, while making selective investments in Europe and Asia. Pappas Capital’s diversified investment strategy reflects its dedication to building companies that drive transformative advancements in the global life sciences and technology sectors.

Hangzhou Yuhang Financial Holdings Group Co., Ltd. was established in October 2022 with a registered capital of RMB 10 billion, and is a state-owned enterprise directly under the Yuhang District People’s Government. The group primarily undertakes key functions such as advancing the securitization of state-owned assets across the district, enhancing its leading role in industry incubation, improving the allocation and operational efficiency of state-owned capital, and building high-end talent service platforms and digital information service platforms.

Hangzhou Yuhang Financial Holdings Group Co., Ltd. has total assets of RMB 88.005 billion and achieved total revenue of RMB 4.869 billion. The group’s government industrial funds have a total scale of RMB 9.8 billion, with subsidiary funds reaching RMB 54.55 billion; it has cumulatively invested in 806 projects, with a total investment amounting to RMB 19.06 billion. In 2022, its policy-based guarantee services supported 283 enterprises, with an outstanding guarantee balance of RMB 610 million; policy-based bridge loan services assisted 2,958 enterprises, facilitating fund turnover of RMB 15 billion. The group has cumulatively participated in the construction of 40 informatization projects for the district government, with several projects successfully selected for the Yuhang District “Chuangjing Plan,” provincial and municipal “Jiebang Guashuai” initiatives, and provincial and municipal pilot projects.